

FOR IMMEDIATE RELEASE

Contact: Ralph Kauten

June 18, 2004

(608) 441-2950
RalphK@Quintbio.com

Madison's Quintessence Biosciences, Inc. Adds Prominent Scientific Leaders to Advisory Board

MADISON, WISCONSIN – Observing that “we lose too many of our friends and family to cancer,” Quintessence Biosciences, Inc. President and CEO Ralph Kauten today announced the formation of a Scientific Advisory Board consisting of distinguished scientific leaders to guide the company in its development of cancer therapeutics. The announcement was made following the Annual Meeting of the American Society of Clinical Oncology in New Orleans, Louisiana.

“Cancer affects one of every three people at some point during their life,” Kauten added. “Quintessence Biosciences must have access to the best medical and scientific guidance in order to successfully turn innovative science into effective medicines. With these scientific advisors, I am confident that we can find the right way.”

Kauten noted that the Scientific Advisors include:

- Howard H. Bailey, M.D. Associate Professor in the departments of Medicine, Obstetrics and Gynecology of the University of Wisconsin Comprehensive Cancer Center;
- Thomas J. Burke, Ph.D., faculty member at the University of Wisconsin – Madison and co-founder and former Chief Scientific Officer of PanVera Corporation;
- Anthony J. Clemento, Jr., former Vice President for Scientific and Regulatory Consulting for Covance Laboratories;
- Laura L. Kiessling, Ph.D. Professor of Chemistry and Biochemistry at the University of Wisconsin – Madison and co-founder of Quintessence Biosciences, Inc.;

-more-

Quintessence/Page two

- Ronald T. Raines, Ph.D. Professor of Biochemistry and Chemistry at the University of Wisconsin – Madison, co-founder of Quintessence Biosciences, Inc. and inventor of the EVade™ ribonuclease technology; and
- Paul M. Sondel, M.D., Ph.D. Professor in the departments of Pediatrics, Human Oncology, and Genetics at the University of Wisconsin Comprehensive Cancer Center.

According to Kauten, the Scientific Advisory Board will help to supplement the scientific and medical expertise within Quintessence Biosciences, Inc. They will also assist the company as it designs, conducts and evaluates its drug development plan, including the results of its preclinical and clinical studies.

“The technology of Quintessence Biosciences is very appealing,” said Dr. Paul Sondel. “The company’s EVade™ ribonuclease technology offers hope that may lead to future treatment.”

Founded in 2003, Quintessence Biosciences, Inc. is a company engaged in creating products based on chemistry and biochemistry technologies discovered at the University of Wisconsin-Madison and licensed from the Wisconsin Alumni Research Foundation (WARF). Principal among the assets of Quintessence Biosciences are newly patented technologies that allow for the creation of drug therapies using human proteins (EVade™ ribonuclease technology). The Board’s formation follows the successful completion of financial transactions and the formation of a Business Advisory Board.

###

(Quintessence Biosciences, Inc. is a biotechnology company engaged in developing therapeutic products and tools for biological research. The company consists of a team of people dedicated to expanding the knowledge of science for the betterment of life within an environment of encouraged exploration and achievement. For more information go to: <http://www.quintbio.com>